Nitrosamine Risk Assessment & Control for Pharmaceutical Products

Risk-based nitrosamine assessment, toxicological evaluation, and regulatory documentation aligned with EMA, FDA, and global regulatory expectations.

Bioexcel supports pharmaceutical manufacturers


Bioexcel supports pharmaceutical manufacturers in identifying, assessing, controlling, and documenting nitrosamine risks across drug substances, drug products, and manufacturing processes.

Our nitrosamine risk assessments follow a science-based, regulator-aligned approach, ensuring compliance with current EMA, FDA, and global regulatory guidance and suitability for inspections, audits, and regulatory submissions.

We help manufacturers proactively manage nitrosamine risks, minimize regulatory exposure, and ensure patient safety.

WHAT WE SUPPORT

  • Nitrosamine risk identification and assessment
  • Toxicological evaluation and Acceptable Intake (AI) derivation
  • Risk control and mitigation strategies
  • Regulatory documentation and authority responses
  • Inspection and audit readiness

Nitrosamine Risk Assessment Services

Nitrosamine Risk Identification & Assessment

Systematic evaluation of potential nitrosamine formation risks arising from: – Active pharmaceutical ingredients (APIs) – Excipients -Manufacturing processes and intermediates – Packaging materials and storage conditions
Assessments are aligned with EMA and FDA guidance.

Toxicological Evaluation & Acceptable Intake (AI)

Derivation and justification of Acceptable Intake (AI) limits using: – Available toxicological data – Structure– activity relationship (SAR) analysis – Threshold of Toxicological Concern (TTC) principles.
Prepared to support regulatory review and inspection.

Risk Control & Mitigation Strategies

Development of scientifically justified mitigation strategies including: – Process optimization and controls – Raw material and supplier qualification – Manufacturing and storage condition controls
Documented to meet regulatory expectations.

Regulatory Documentation & Authority Responses

Preparation of: – Nitrosamine risk assessment reports Regulatory response documentation Inspectionready justifications and summaries
Aligned with submission and inspection requirements.

Alignment & Documentation

Regulatory & Guidance Alignment

Nitrosamine services are aligned with: – EMA guidance on nitrosamine impurities – FDA nitrosamine recommendations – ICH Q9 (Quality Risk Management) – Toxicological risk assessment best practices

Integration with Pharma Compliance Activities

Built for Inspections and Audits

Nitrosamine risk assessment outputs integrate with: – PDE, OEL & CLP (Pharma) – Cleaning Validation (Pharma) – Extractables & Leachables (Pharma)
Ensuring consistent toxicological justification across all pharma compliance activities.

Who This Service Is For

  • Pharmaceutical manufacturers
  • API manufacturers
  • Quality Assurance and Regulatory Affairs teams
  • Companies responding to regulatory authority requests

Why Bioexcel

  • Dedicated pharma toxicology expertise
  • Regulator-aligned nitrosamine assessment methodology
  • Inspection-ready documentation
  • Clear separation from medical device toxicology services

Address Nitrosamine Risks with Confidence

Bioexcel helps pharmaceutical companies assess, control, and document nitrosamine risks in line with current regulatory expectations.